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renal disease (ESRD), developing ESRD with chronic renal failure, and developing ESRD with uncorrected bilateral RAS; mortality rates; incidence of non-RAS hypertension;
incidence of non-RAS renal insufficiency; the sensitivity and specificity of magnetic resonance angiography; and the sensitivity and specificity of diagnostic angiography.
Estimates were also provided for the success rates of hypertension medication, surgery and stenting, and the rates of azotemia stabilised or improved by surgery or stenting.
Study designs and other criteria for inclusion in the review
The authors developed a decision analysis model, using Markov techniques, to predict the health pathways of patients with RAS, following PTA-S or delayed PTA-S. The parameters for the model were populated using findings from published literature. The authors did not state any exclusion or inclusion criteria.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The effectiveness data were derived from 17 studies. The cost data were taken from three published studies, as well as Professional Reimbursement databases.
